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Demography, baseline characteristics and 
treatment history of patients with psoriasis in a 
disease-based registry
Kimball et al. open this paper by stating that psoriasis is associ-
ated with several comorbidities and behavioural risk factors. 
Their objective was to evaluate demographic and disease char-
acteristics in patients enrolled into a psoriasis registry. Their 
registry is global, prospective, longitudinal and disease based; 
it includes postmarketing evaluation of safety in patients with 
psoriasis. Registry enrolment required patients to be receiving, 
or eligible to receive, conventional systemic or biological 
agents. Demographic/disease characteristics, medical histories, 
lifestyle risk factors and previous treatments were collected at 
enrolment. Efficacy and safety data were then collected every 
6 months for 8 years. By 23 August 2012, a total of 11 900 
patients had been enrolled at 301 sites in North America, 
Europe and Latin America. Over half of the registry popula-
tion (54.7%) was male, their mean age was 48.6 years and 
mean body mass index 30.9 kg m−2 at enrolment. The mean 
duration of disease at enrolment was 17.5 years, and the mean 
Physician’s Global Assessment score was 2.0. The authors 
reported that psoriatic arthritis (35.5%) and cardiovascu-
lar diseases (38.2%) were highly prevalent in patients within 
this registry. Diabetes mellitus type II was reported in 11.4% 
of patients. Depression and anxiety were noted in 14.7% and 
11.1% of patients, respectively; 79.0% reported any alcohol 
use and 56.7% reported smoking or a history of smoking. The 
occurrence of most comorbidities, including cardiovascular 
disease and risk factors, increased with age. The authors con-
cluded that multiple, age-appropriate comorbidities were 
associated with psoriasis in this registry population, which 
may impact the selection of psoriasis treatments. Br J Dermatol 
2014; 171: 137–147.
Skin irritability to sodium lauryl sulfate  
is associated with increased positive patch  
test reactions
Schwitulla and colleagues open this paper by acknowledging 
the inter-relationship between irritant and allergic skin reac-
tions. In order to characterize this better, they analysed data 
of synchronous allergen and sodium lauryl sulfate (SLS) patch 
tests in terms of a relationship between SLS responsiveness 
and allergic patch test reactions. Their aim was to analyse dif-
ferences in terms of allergen speciﬁcity and overall reaction 
proﬁles between patients with and without an irritant reaction 
to SLS. The study involved analysis of clinical data of the 26 
879 patients patch tested from 2008 to 2011 by members of 
the IVDK network (www.ivdk.org). A negative binomial hurdle 
model was adopted to investigate the correlation between SLS 
reactivity and positive patch test reactions. The results showed 
that male patients, patients aged ≥ 40 years and patients with 
an occupational background were over-represented in the SLS-
reactive group. Patients with an irritant reaction to SLS showed 
a higher proportion of weak positive reactions, as well as more 
questionable and irritant reactions to contact allergens, than 
patients not reactive to SLS. The risk of an additional positive 
patch test reaction increased by 22% for SLS-reactive patients 
vs. SLS-negative ones. The authors concluded that the marked 
association between SLS reactivity and the number of positive 
reactions in patch tested patients may be due to nonspeciﬁc 
increased skin reactivity at the moment of patch testing only. 
The authors speculated that increased SLS reactivity may be due 
to longer-lasting enhanced skin irritability, which may have pro-
moted (poly)sensitization. Br J Dermatol 2014; 171: 115–123.
Antihypertensive drugs and rosacea
Spoendlin et al. commence by stating that in spite of scarce 
evidence, the use of calcium channel blockers is discour-
aged in patients with rosacea, whereas beta-blockers are 
recom-mended as an off-label treatment for erythematotel-
angiectatic rosacea. Their aim was to study the association 
of the use of calcium channel blockers, beta-blockers and 
other antihypertensive drugs with incident rosacea. They car-
ried out a matched case–control study of antihypertensive 
drugs and incident rosacea, using the U.K.-based General 
Practice Research Database. Included cases had a ﬁrst diag-
nosis of rosacea recorded between 1995 and 2009. Each case 
was matched to one control for age, sex, general practice and 
years of history on the database before the index date. Drug 
use was stratiﬁed by timing (≤ or > 180 days before the index 
date) and duration (number of prescriptions) of drug expo-
sure, in a multivariate conditional logistic regression model. 
The study included 53 927 cases and 53 927 controls. They 
observed odds ratios (ORs) around unity for calcium channel 
blockers across all strata, with a slightly decreased OR of 0.77 
(95% conﬁdence interval 0.69–0.86) for current users of dihy-
dropyridine calcium channel blockers with ≥ 40 prescriptions. 
Among beta-blockers, atenolol and bisoprolol yielded slightly 
decreased ORs across all exposure strata, whereas propranolol 
revealed ORs around 1.0, irrespective of timing and duration 
of exposure. Neither angiotensin-converting enzyme inhibi-
tors nor angiotensin receptor blockers altered the relative rosa-
cea risk. The authors concluded that their data contradicted 
the prevailing notion that calcium channel blockers increase 
the risk of rosacea. Furthermore, beta-blocker use was associ-
ated with a slightly decreased risk of rosacea. Br J Dermatol 
2014; 171: 130–136.
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